Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in Newton, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-600-6888
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees57
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Stealth BioTherapeutics (NASDAQ:MITO) Frequently Asked Questions
What is Stealth BioTherapeutics' stock symbol?
Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO."
How were Stealth BioTherapeutics' earnings last quarter?
Stealth BioTherapeutics Corp (NASDAQ:MITO) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.04. View Stealth BioTherapeutics' Earnings History.
When is Stealth BioTherapeutics' next earnings date?
What price target have analysts set for MITO?
6 Wall Street analysts have issued twelve-month price objectives for Stealth BioTherapeutics' shares. Their forecasts range from $9.00 to $35.00. On average, they expect Stealth BioTherapeutics' stock price to reach $23.33 in the next twelve months. This suggests a possible upside of 243.6% from the stock's current price. View Analyst Price Targets for Stealth BioTherapeutics.
What is the consensus analysts' recommendation for Stealth BioTherapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stealth BioTherapeutics.
Has Stealth BioTherapeutics been receiving favorable news coverage?
Media headlines about MITO stock have trended very negative this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Stealth BioTherapeutics earned a news impact score of -3.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Stealth BioTherapeutics.
Who are some of Stealth BioTherapeutics' key competitors?
Some companies that are related to Stealth BioTherapeutics include Amphastar Pharmaceuticals (AMPH), Phibro Animal Health (PAHC), Athenex (ATNX), Axsome Therapeutics (AXSM), Achillion Pharmaceuticals (ACHN), Karyopharm Therapeutics (KPTI), G1 Therapeutics (GTHX), Principia Biopharma (PRNB), Eagle Pharmaceuticals (EGRX), Cara Therapeutics (CARA), Dova Pharmaceuticals (DOVA), ZIOPHARM Oncology (ZIOP), Amneal Pharmaceuticals (AMRX), CannTrust (CNTTF) and Arvinas (ARVN).
What other stocks do shareholders of Stealth BioTherapeutics own?
Who are Stealth BioTherapeutics' key executives?
Stealth BioTherapeutics' management team includes the folowing people:
- Ms. Irene P. McCarthy J.D., Pres ,CEO, Sec. & Director (Age 54)
- Mr. Daniel E. Geffken, Interim Chief Financial Officer (Age 62)
- Mr. Mark J. Bamberger, Chief Scientific Officer (Age 66)
- Mr. Henry Hess, Chief Legal Counsel
- Dr. Ben R. Bronstein, Chief Medical Officer (Age 69)
When did Stealth BioTherapeutics IPO?
(MITO) raised $81 million in an initial public offering on Friday, February 15th 2019. The company issued 6,200,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets served as the underwriters for the IPO and Nomura was co-manager.
How do I buy shares of Stealth BioTherapeutics?
Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Stealth BioTherapeutics' stock price today?
One share of MITO stock can currently be purchased for approximately $6.79.
How big of a company is Stealth BioTherapeutics?
Stealth BioTherapeutics has a market capitalization of $237.85 million. The company earns $-96,710,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Stealth BioTherapeutics employs 57 workers across the globe.View Additional Information About Stealth BioTherapeutics.
What is Stealth BioTherapeutics' official website?
How can I contact Stealth BioTherapeutics?
Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company can be reached via phone at 617-600-6888 or via email at [email protected]
MarketBeat Community Rating for Stealth BioTherapeutics (NASDAQ MITO)
MarketBeat's community ratings are surveys of what our community members think about Stealth BioTherapeutics and other stocks. Vote "Outperform" if you believe MITO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MITO will underperform the S&P 500 over the long term. You may vote once every thirty days.
